MedTrace Logo

Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

NCT03803228 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-12-07

No results posted yet for this study

Summary

During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).

Conditions

  • Fertility Disorders

Interventions

DRUG

DUOSTIM

2 consecutive stimulations by Fertistartkit® on the same cycle

DRUG

Conventional stimuli

2 stimulations by Fertistartkit® performed on 2 different cycles

Sponsors & Collaborators

  • Laboratoires Genévrier

    collaborator INDUSTRY

  • IBSA Institut Biochimique SA

    collaborator INDUSTRY

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Principal Investigators

  • Nathalie MASSIN, MD · CHI Créteil

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-03
Primary Completion
2021-03-03
Completion
2021-11-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03803228 on ClinicalTrials.gov